Celator Pharmaceuticals (NASDAQ:CPXX) should head towards $26.25 per share according to 6 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $20 per share. The higher price estimate target is at $30 according to the Analysts.
Many analysts have stated their opinion on the company shares. Stifel Nicolaus downgrades its view on Celator Pharmaceuticals (NASDAQ:CPXX) according to the research report released by the firm to its investors. The shares have now been rated Hold by the stock experts at the ratings house. Earlier, the shares had a rating of Buy. The rating by the firm was issued on June 1, 2016. Company shares have received an average consensus rating of Hold for the current week
On the companys insider trading activities, Morenstein Scott D, director of Celator Pharmaceuticals Inc had purchased 5,000 shares on December 3, 2015 in a transaction. The price per share was $1.87 and the total amount of the disclosed transaction was $9,350.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Celator Pharmaceuticals (NASDAQ:CPXX) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.11 points or 0.36% at $30.13 with 1,923,356 shares getting traded. Post opening the session at $30.19, the shares hit an intraday low of $30.07 and an intraday high of $30.25 and the price was in this range throughout the day. The company has a market cap of $1,280 million and the number of outstanding shares have been calculated to be 42,470,256 shares. The 52-week high of Celator Pharmaceuticals (NASDAQ:CPXX) is $30.365 and the 52-week low is $1.12.
Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing products to cure cancer. Celators technology platform, CombiPlex, offers the rational design and rapid evaluation of combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Companys products are in research and development phases. Celators lead product is CPX-351, a liposomal formulation of cytarabine:daunorubicin for the treatment of acute myeloid leukemia. The Company owns worldwide development and commercialization rights to CPX-351. The Companys other pipeline products includes CPX-1, a liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer, and a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation.